Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
CPRX Stock Chart & Stats
$22.78
-$0.35(-1.79%)
At close: 4:00 PM EST
$22.78
-$0.35(-1.79%)
Day’s Range― - ―
52-Week Range$19.05 - $26.58
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.43M
Market Cap
$2.80B
Enterprise Value$1.82B
Total Cash (Recent Filing)$689.89M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)13.3
Beta0.77
Next Earnings
Mar 18, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding122,912,384
10 Day Avg. Volume1,615,661
30 Day Avg. Volume1,434,361
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.40
Price to Sales (P/S)5.03
P/FCF Ratio10.33
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue3.14
Enterprise Value/Gross Profit3.76
Enterprise Value/Ebitda5.97
Forecast
1Y Price Target
$34.00Price Target Upside49.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.55
Revenue Forecast (FY)$575.01M
Bulls Say, Bears Say
Bulls Say
Agamree Launch SuccessThe strength of the Agamree launch continues to exceed expectations, with significant revenue and broad adoption across legacy corticosteroid segments.
Expansion In OncologyCancer-associated LEMS is expected to be a key driver for the next phase of growth for Firdapse, highlighting significant unmet need and opportunity for expansion.
Patent Litigation ResolutionCatalyst has settled with 3 of the 4 filers in ongoing patent litigation for Firdapse, which bodes well for the company.
Bears Say
Conservative Guidance Due To GenericsManagement flagged risk of additional generics as rationale for conservative FY25 guide.
Firdapse Revenue MissFirdapse revenue missed consensus due to underestimated impact from insurance claims disruption.
Generic Competition For FycompaMultiple generics entering the market are expected to result in more impactful erosion of Fycompa revenue, affecting performance in future periods.
Catalyst Pharma News
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $19.05 and its highest was $26.58 in the past 12 months.
What is Catalyst Pharma’s market cap?
Catalyst Pharma’s market cap is $2.80B.
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is Mar 18, 2026 which is in 124 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on Nov 05, 2025. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.332 by $0.088.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is 0.31.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 122,912,384 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.42 in its last earnings report, beating expectations of $0.332. Following the earnings report the stock price went down -1.824%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Currently, no hedge funds are holding shares in CPRX
Catalyst Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (49.25% Upside)
$34.00 (49.25% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 561.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $987.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.12%
12-Months-Change
Fundamentals
Return on Equity
27.52%
Trailing 12-Months
Asset Growth
36.22%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals, Inc. (CPRX) is a biopharmaceutical company focused on developing innovative therapies for people with rare neurological diseases. The company primarily operates in the pharmaceutical sector and is known for its flagship product, Firdapse (amifampridine), which is approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and is being explored for other rare conditions. Catalyst Pharma aims to address unmet medical needs through its specialized drug development and commercialization efforts.
CPRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Catalyst Pharmaceuticals' strong financial performance, driven by significant growth in FIRDAPSE and AGAMREE, as well as the company's solid cash position and raised revenue guidance. However, the decline in FYCOMPA revenue due to generic competition and ongoing patent litigation for FIRDAPSE were noted challenges.View all CPRX earnings summariesCPRX Stock 12 Month Forecast
Average Price Target
$34.00
▲(49.25% Upside)
Technical Analysis
Amicus
―
Travere Therapeutics
―
Ocular Therapeutix
―
ImmunityBio
―
Liquidia Technologies
―
Ownership Overview
6.16% Insiders
17.46% Mutual Funds
8.56% Other Institutional Investors
42.66% Public Companies and Individual Investors